Overview of ANNEX 1

Modifications and Impacts

May 15, 2020

15 May 2020
(Duration : 90 mins)

Gilberto DALMASO,
Pharma and Medical Devices Consulting Owner at GDM Pharma Consulting

Félix MONTERO,
bioMérieux Industry Global Scientific Director

Overview of Annex 1 modifications and impacts.

WRITTEN BY

Scientific Director Healthcare Business
Healthcare Business Industry Unit
bioMérieux SA, France

WRITTEN BY

Pharma and Medical Devices Consulting Owner
GDM Pharma Consulting